Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Disc Medicine, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
09/29/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
08/11/2023 8-K Quarterly results
06/16/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among the Company and Morgan Stanley & Co. LLC, SVB Securities LLC, Stifel, Nicolaus & Company, Incorporated, and BMO Capital Markets Corp., as representatives of the several underwriters listed on Schedule A thereto",
"Form of Pre-Funded Warrant",
"Opinion of Goodwin Procter LLP regarding the issue of Common Stock, Pre-Funded Warrants and Common Stock issuable upon exercise of the Pre-Funded Warrants being registered",
"Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants",
"Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants"
06/12/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/09/2023 8-K Investor presentation
Docs: "Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria at European Hematology Association 2023 Congress",
"Disc Medicine, Inc. Investor Presentation, furnished herewith"
05/15/2023 8-K Quarterly results
Docs: "Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update"
04/19/2023 8-K Quarterly results
03/31/2023 8-K Quarterly results
02/14/2023 8-K Quarterly results
01/25/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Sales Agreement by and between Disc Medicine, Inc. and SVB Securities LLC",
"Opinion of Goodwin Procter LLP"
01/23/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis",
"Disc Medicine, Inc. Corporate Presentation, furnished herewith"
12/29/2022 8-K Acquisition/merger/asset purchase announced
Docs: "Common Stock Issuance Agreement, by and between Disc Medicine Opco, Inc., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc"
12/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting",
"Social media posts, posted by Disc Medicine, Inc. on December 13, 2022"
12/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/10/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
04/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/10/2022 8-K Quarterly results
Docs: "Gemini Therapeutics Reports 2021 Financial Results"
02/28/2022 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Separation Agreement and Release, by and between Gemini Therapeutics, Inc. and Jason Meyenburg",
"Gemini Therapeutics Provides Corporate Update Remote-First-Company/Mass. - February 28, 2022 - Gemini Therapeutics, Inc. , a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration , today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company's current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company. Additionally, the Company has initiated a process to evaluate strategic alternatives in order to maximize shareholder va..."
01/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
01/10/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Gemini Therapeutics Provides GEM103 Program Update"
11/15/2021 8-K Quarterly results
Docs: "Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update"
11/12/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Gemini Therapeutics Announces Poster Presentation at AAO 2021"
10/06/2021 8-K Quarterly results
10/01/2021 8-K Quarterly results
09/09/2021 8-K Quarterly results
08/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/12/2021 8-K Quarterly results
06/23/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/07/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : May 7, 2021 GEMINI THERAPEUTICS, INC. Delaware 001-39438 85-1612845 300 One Kendall Square, 3rd Floor Cambridge, MA 02139 401-4400 Not Applicable Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencements communications pursuant to Rule 13e-4 und..."
04/14/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "THE COMPANY'S PRESS RELEASE, DATED APRIL 12, 2021"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy